BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 613
- Registration Number
- NCT00402467
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 726
- Registration Number
- NCT00398905
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 877
- Registration Number
- NCT00396786
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00395733
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 147
- Registration Number
- NCT00395460
- Locations
- 🇨🇳
Fudan University Huashan Hospital, Shanghai, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an, Shaanxi, China
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 543
- Registration Number
- NCT00395772
Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 204
- Registration Number
- NCT00393198
Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 352
- Registration Number
- NCT00377793
Dose Escalation Study of SH U04722 in Solid Tumors
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00375453
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-30
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT00370071
© Copyright 2024. All Rights Reserved by MedPath